Provigil Cost in South Dakota 2026: What You'll Actually Pay

How Much Does Provigil Cost in South Dakota in 2026?

Brand Provigil (modafinil 200 mg, Cephalon) carries a manufacturer list price of $850 per month in South Dakota as of 2026. Generic modafinil, available from multiple manufacturers including Sun Pharmaceutical and Teva, averages approximately $80 per month at retail pharmacies across the state on a cash-pay basis. The gap between those two figures is large enough that most patients and prescribers default to generic immediately.

Brand vs. Generic: The Price Breakdown

The $770 monthly difference between brand and generic is not a rounding error. It reflects the patent expiration field for modafinil, which lost U.S. Exclusivity in 2012. Since then, generic entrants have steadily compressed the cash price at pharmacies in Rapid City, Sioux Falls, Aberdeen, and smaller SD communities.

A 30-tablet supply of generic modafinil 200 mg at major SD retail chains (Walgreens, Hy-Vee Pharmacy, Sanford Health Pharmacy) typically ranges from $65 to $95 depending on the dispensing pharmacy and the patient's use of discount cards. GoodRx and similar programs can push that figure below $60 at select locations.

What Drives Price Variation Across SD Pharmacies?

Several factors shift the final number a South Dakota patient pays:

• Discount card applied vs. Not applied. GoodRx, RxSaver, and manufacturer-linked programs routinely cut cash-pay prices 20 to 40 percent below the pharmacy's posted retail price.
• Pharmacy type. Independent pharmacies in smaller SD cities (Watertown, Brookings, Mitchell) sometimes negotiate differently with wholesalers than national chains.
• Quantity dispensed. A 90-day supply often costs less per tablet than three separate 30-day fills.
• Dose strength. Modafinil 100 mg tablets, sometimes prescribed for dose titration, may carry a different per-unit cost than 200 mg tablets.

Patients should call at least two pharmacies before filling and ask for the cash price with their discount card applied before assuming the first quoted price is final.

Does South Dakota Medicaid Cover Provigil?

South Dakota Medicaid does not cover Provigil (brand or generic modafinil) for narcolepsy, obstructive sleep apnea adjunct, or shift-work sleep disorder as of 2026. The state's preferred drug list excludes modafinil without a documented prior-authorization pathway that reaches approval for most enrollees.

Why Medicaid Denials Happen

South Dakota's Medicaid program, administered under the SD Department of Social Services, follows a closed formulary approach for wakefulness-promoting agents. Modafinil sits in a therapeutic category where the state has historically preferred older, less expensive alternatives for daytime sleepiness. Prescribers have submitted prior-authorization requests citing specific polysomnographic data and documented CPAP failure, with mixed results.

The Centers for Medicare and Medicaid Services publishes state-level formulary guidance, and South Dakota's preferred drug list is updated quarterly. Patients enrolled in SD Medicaid managed-care plans (Wellcare of South Dakota, Sanford Health Plan Medicaid) should confirm their specific plan's formulary, because managed-care contracts occasionally differ from straight fee-for-service coverage. [Check CMS coverage tools at nih.gov or cms.gov for the most current formulary status.]

Medicare Part D in South Dakota

Medicare Part D plans operating in South Dakota vary widely. Some Part D formularies do include generic modafinil on Tier 3 or Tier 4, meaning a patient with a documented narcolepsy diagnosis and a valid prescription might pay $40 to $120 per month depending on the plan's copay structure and whether the deductible phase has been satisfied. South Dakota residents should use the Medicare Plan Finder at medicare.gov each October during open enrollment to compare which Part D plans include modafinil on their 2026 formularies.

Is Compounded Modafinil Legal in South Dakota?

503A-compounded modafinil is available through licensed compounding pharmacies operating under South Dakota state pharmacy law and federal DEA Schedule IV requirements. The legality is not in dispute for pharmacies holding the correct licensure, but patients need a valid prescription from a licensed prescriber.

What 503A Means for South Dakota Patients

A 503A pharmacy compounds medications for individual patients based on a specific prescription. This differs from a 503B outsourcing facility, which produces larger commercial batches. South Dakota has licensed 503A compounding pharmacies, and a prescriber practicing in the state can write a prescription for compounded modafinil if a valid patient-specific clinical rationale exists.

The FDA does not approve compounded drugs as finished products, and the agency's guidance on compounding Schedule IV controlled substances requires that the compounding pharmacy and the dispensing state both authorize the practice. South Dakota's Board of Pharmacy has not issued a specific prohibition on compounded modafinil for Schedule IV substances when all licensure requirements are met. Patients interested in this route should confirm their compounding pharmacy's DEA registration and South Dakota Board of Pharmacy status before proceeding. FDA compounding guidance is available at fda.gov.

Cost of Compounded Modafinil in South Dakota

Compounded modafinil pricing varies by pharmacy and formulation. Some 503A pharmacies offer modafinil at a lower monthly cost than retail generics, depending on the base cost of active pharmaceutical ingredient and the pharmacy's dispensing fee. Patients who have confirmed both the clinical appropriateness and the legal pathway sometimes find compounded formulations attractive from a cost standpoint, particularly if they require a non-standard dose or a specific excipient-free formulation for allergy reasons.

Provigil and Insurance Coverage in South Dakota

Private insurance plans in South Dakota cover modafinil inconsistently. Plans sold on the South Dakota ACA marketplace through healthcare.gov, as well as employer-sponsored plans governed by ERISA, each apply their own formulary logic.

Typical Private Insurance Coverage Patterns

Most commercial plans that do cover modafinil place generic versions on Tier 2 or Tier 3, with copays ranging from $25 to $75 per month after the deductible is satisfied. Brand Provigil, when covered at all, typically lands on Tier 4 or Tier 5, creating a cost-sharing responsibility that can exceed $200 per month even with insurance.

The most common prior-authorization requirements for modafinil under SD commercial plans include:

• An ICD-10 diagnosis of narcolepsy (G47.419), obstructive sleep apnea (G47.33), or shift-work sleep disorder (G47.26)
• A sleep study or clinical documentation supporting the diagnosis
• Prescriber attestation that the patient has tried and failed at least one behavioral or lifestyle intervention

Without prior authorization approval, claims for modafinil are typically rejected at the point of sale, leaving the patient to pay cash.

Appealing an Insurance Denial in South Dakota

South Dakota residents have the right to a formal internal appeal and, if that fails, an external independent review under state insurance law and the ACA. The SD Division of Insurance handles complaints and can guide patients through the external review process. A prescriber's detailed clinical letter citing diagnostic criteria from the American Academy of Sleep Medicine (AASM) guidelines is the single most useful document in an appeal.

Can I Get Provigil via Telehealth in South Dakota?

Yes. Telehealth prescribing of modafinil is legal in South Dakota when the prescribing clinician holds an active South Dakota medical license and a DEA Schedule IV controlled substance registration that covers South Dakota. The prescriber must conduct a clinically appropriate evaluation before issuing a Schedule IV prescription.

What the Telehealth Visit Looks Like

A telehealth consultation for modafinil typically involves a structured intake covering sleep history, Epworth Sleepiness Scale scoring, prior diagnostic workup (polysomnography or actigraphy where relevant), and a review of medications and comorbidities. The prescriber may request records from a prior sleep study before prescribing.

After a valid prescription is issued, the patient can take it to any South Dakota retail pharmacy or use a mail-order pharmacy registered to dispense in SD. Telehealth platforms that specialize in sleep medicine or cognitive health often have prescribers already licensed in South Dakota, making access straightforward for patients in rural areas like the Black Hills region or the Missouri River corridor.

The DEA's temporary telehealth flexibilities that expanded Schedule IV prescribing during the COVID-19 public health emergency have been subject to ongoing regulatory review. Patients should confirm with their telehealth provider that the current DEA rules allow prescribing of Schedule IV substances via telehealth without a prior in-person visit, as this policy has evolved. See DEA guidance at dea.gov and FDA updates at fda.gov.

The Clinical Evidence Behind Modafinil: Why Prescribers Write It

Modafinil received FDA approval for narcolepsy in 1998, for obstructive sleep apnea adjunct therapy in 2003, and for shift-work sleep disorder in 2003. The Provigil prescribing information is available at the FDA's access data portal.

The Key Narcolepsy Trial

The US Modafinil in Narcolepsy Multicenter Study Group published a randomized, double-blind, placebo-controlled trial in Annals of Neurology (1998, N=271) showing that modafinil 200 mg and 400 mg produced statistically significant reductions in daytime sleepiness versus placebo, as measured by the Multiple Sleep Latency Test and the Epworth Sleepiness Scale. That trial is indexed at PubMed. This study formed a core part of the FDA's efficacy basis for approval.

The AASM's clinical practice guidelines for narcolepsy state that modafinil is recommended as a standard-of-care wakefulness-promoting agent based on high-quality evidence from multiple randomized controlled trials. To quote the guideline directly: "Modafinil is recommended for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy (STANDARD)."

Shift-Work Sleep Disorder Evidence

A randomized trial published in the New England Journal of Medicine (Czeisler et al., 2005, N=278) demonstrated that modafinil 200 mg taken approximately one hour before the night shift reduced sleepiness during the shift and improved performance on cognitive tests compared to placebo, with a mean improvement of 1.7 points on the Karolinska Sleepiness Scale (P<0.001). See the NEJM publication for full methodology.

The HealthRX clinical team uses a structured three-tier cost decision framework for South Dakota patients prescribed modafinil:

Tier 1 (Try first): Generic modafinil at retail with a discount card. Expected cost: $60 to $95/month. Available same-day at most SD pharmacies.

Tier 2 (If Tier 1 is cost-prohibitive or fails formulary): Submit a prior-authorization to the patient's commercial insurer or Part D plan with full diagnostic documentation. If approved, copay drops to $25 to $75/month in most plans.

Tier 3 (For patients with allergy, formulation, or access barriers): 503A compounded modafinil from a South Dakota-licensed compounding pharmacy with DEA registration. Requires a new prescription specifying compounded product.

Discount Programs and Savings Cards for Provigil in South Dakota

Several programs reduce out-of-pocket modafinil costs for South Dakota residents who do not have coverage or whose coverage is insufficient.

GoodRx and Competing Discount Cards

GoodRx, RxSaver, and Blink Health operate in South Dakota and contract with retail pharmacies to offer below-retail cash prices. For generic modafinil 200 mg (30 tablets), prices in Sioux Falls and Rapid City pharmacies through these programs have ranged from $55 to $90 in early 2026. Prices change weekly based on pharmacy contracts, so patients should check the app the day of fill.

These programs are not insurance. They cannot be combined with a Medicaid or Medicare claim. Patients on government programs must choose one or the other for each prescription fill.

Manufacturer Patient Assistance Programs

Cephalon (now part of Teva) historically offered a patient assistance program for brand Provigil for uninsured patients meeting income eligibility thresholds. Patients should contact Teva's patient assistance line directly and ask specifically about modafinil eligibility, because program terms change annually and South Dakota residents may qualify based on income relative to federal poverty level.

Generic manufacturers do not typically offer branded savings cards, but the discount card system described above effectively serves the same function.

NeedyMeds and State Pharmaceutical Assistance

The NeedyMeds database (needymeds.org) lists patient assistance programs by drug and state. South Dakota does not operate a state pharmaceutical assistance program for modafinil specifically, but some county health departments and federally qualified health centers (FQHCs) in SD have drug sample programs or can connect patients with manufacturer assistance.

How Modafinil Is Dosed in South Dakota Clinical Practice

Prescribers in South Dakota follow the FDA-approved dosing schedule for modafinil's three approved indications. The standard approach is not one-size-fits-all, and a prescriber may adjust based on tolerability.

Narcolepsy and Obstructive Sleep Apnea

The approved starting dose is 200 mg orally once each morning. Some patients with severe daytime sleepiness are titrated to 400 mg/day, though the FDA label notes that doses above 200 mg/day did not consistently show additional benefit in the narcolepsy trials. For OSA, modafinil is used as an adjunct to CPAP therapy, not a replacement. Prescribers confirm CPAP adherence before continuing modafinil for OSA patients.

Shift-Work Sleep Disorder

Patients with SWSD take 200 mg approximately one hour before beginning their night shift. The dose is not taken on days when the patient does not work a night shift, which means monthly consumption and cost can be lower than the standard 30-tablet/month assumption.

Off-Label Use

Modafinil is prescribed off-label for conditions including multiple sclerosis-related fatigue, cancer-related fatigue, and cognitive symptoms in certain psychiatric conditions. South Dakota prescribers writing for off-label indications face stricter insurance denial rates, and cash-pay is the common outcome for those patients. The FDA has not approved modafinil for cognitive enhancement in healthy individuals, and off-label prescribing for that purpose is not endorsed by any major clinical guideline.

Side Effects and Contraindications South Dakota Patients Should Know

Modafinil is generally well tolerated at 200 mg/day. The most commonly reported adverse effects in randomized trials include headache (occurring in approximately 34% of patients in the narcolepsy trials), nausea (11%), nervousness (7%), and insomnia (5%).

Serious but rare concerns include Stevens-Johnson syndrome and other serious skin reactions, which led to an FDA safety communication. Modafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. Patients with a history of left ventricular hypertrophy or mitral valve prolapse should be evaluated carefully before initiation due to the drug's mild sympathomimetic activity.

Drug interactions are clinically relevant. Modafinil induces CYP3A4 and can reduce plasma concentrations of hormonal contraceptives by approximately 20%, meaning patients relying on oral contraceptives should use a backup contraceptive method during modafinil treatment and for one month after stopping. Full prescribing information including drug interaction tables is available at the FDA's access data portal.